Bill > SB1525

This bill modifies Texas insurance regulations regarding prior authorization for prescription drugs used to treat neurodegenerative diseases. Specifically, the bill amends existing law to limit health benefit plan issuers to requiring only one prior authorization per year for prescription drugs treating autoimmune and neurodegenerative diseases, with an additional provision allowing insurers to require a new prior authorization when a patient is prescribed a new drug for a neurodegenerative condition. The bill updates the legal subchapter heading to explicitly include neurodegenerative diseases and provides that these changes will apply to health benefit plans delivered, issued, or renewed on or after January 1, 2026. The legislation aims to reduce administrative barriers for patients by restricting the frequency of prior authorization requirements, which can often delay or complicate access to necessary medications. The bill will take effect on September 1, 2025, giving insurers time to adapt their processes to the new requirements.

Business and Industry, Health and Social Services

https://capitol.texas.gov/BillLookup/History.aspx?LegSess=89R&Bill=SB1525